Company research
Panbela Therapeutics, Inc.
CIK 1029125Updated Sep 26, 2026
Name history
Sun BioPharma, Inc. · through Dec 2, 2020Cimarron Medical, Inc. · through Sep 4, 2015CIMARRON SOFTWARE INC · through May 26, 2015
Filing activity
Latest filing
SEC STAFF ACTION · Sep 29, 2025
50 filings on record · SEC STAFF ACTION, SCHEDULE 13D/A, 8-K, S-8, 4, 424B3.
Recent filings
SEC STAFF ACTION filing
SCHEDULE 13D/A - filed by Nant Capital, LLC regarding Panbela Therapeutics, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Triggering Events That Accelerate or Increase a Direct Financial Obligation · Changes in Control of Registrant
Items 2.04, 5.01
Show 5 more recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 11,802,000Source | 4,978,000Source | 12,872,000Source | 9,813,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,578,000Source | 1,285,000Source | 11,867,000Source | 9,022,000Source |
| Assets, CurrentUSD | 3,060,000Source | 1,777,000Source | 12,279,000Source | 9,757,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 299,000Source | — | — | — |
| Other Assets, NoncurrentUSD | 8,742,000Source | 3,201,000Source | 593,000Source | 56,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 16,512,000Source | 13,027,000Source | 2,660,000Source | 1,365,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 0Source | 1,000Source | 13,000Source | 10,000Source |
| Additional Paid in CapitalUSD | 120,043,000Source | 82,285,000Source | 66,227,000Source | 54,848,000Source |
| Retained Earnings (Accumulated Deficit)USD | -125,497,000Source | -91,094,000Source | -56,161,000Source | -46,026,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 745,000Source | 759,000Source | 133,000Source | -384,000Source |
| Stockholders' Equity Attributable to ParentUSD | -4,710,000Source | -8,049,000Source | 10,212,000Source | 8,448,000Source |
| Liabilities and EquityUSD | 11,802,000Source | 4,978,000Source | 12,872,000Source | 9,813,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,318,000Source | 7,833,000Source | 2,660,000Source | 1,365,000Source |
| Accounts Payable, CurrentUSD | 9,939,000Source | 2,865,000Source | 640,000Source | 554,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,141,000Source | 2,993,000Source | 2,020,000Source | 811,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 4,194,000Source | 5,194,000Source | — | — |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 823,000Source | 1,088,000Source | 1,287,000Source | 1,205,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 7,060,000Source | 2,249,000Source | 631,000Source | -747,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -25,249,000Source | -15,276,000Source | -6,704,000Source | -3,854,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 400,000Source | -656,000Source | -540,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 26,142,000Source | 5,354,000Source | 10,095,000Source | 10,444,000Source |
| Repayments of Long-term DebtUSD | — | — | 0Source | 117,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,293,000Source | -10,582,000Source | 2,845,000Source | 6,573,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 404,000Source | 15,000Source | 12,000Source | 8,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 823,000Source | 1,088,000Source | 1,287,000Source | — |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 400,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | — |
| General and Administrative ExpenseUSD | 5,033,000Source | 6,044,000Source | 4,587,000Source | 3,249,000Source |
| Income Tax Expense (Benefit)USD | -186,000Source | -116,000Source | -488,000Source | -295,000Source |
| Investment Income, InterestUSD | 123,000Source | 14,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -25,263,000Source | -34,933,000Source | -10,135,000Source | -4,768,000Source |
| Nonoperating Income (Expense)USD | 198,000Source | -956,000Source | -613,000Source | 691,000Source |
| Other Nonoperating Income (Expense)USD | -8,000Source | -682,000Source | -602,000Source | 605,000Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -25,647,000Source | -34,093,000Source | -10,010,000Source | -5,754,000Source |
| Other Nonoperating Income (Expense)USD | -8,000Source | -682,000Source | -602,000Source | 605,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -25,449,000Source | -35,049,000Source | -10,623,000Source | — |
| Income Tax Expense (Benefit)USD | -186,000Source | -116,000Source | -488,000Source | -295,000Source |
| Net Income (Loss) Attributable to ParentUSD | -25,263,000Source | -34,933,000Source | -10,135,000Source | -4,768,000Source |
| Earnings Per Share, BasicUSD per share | -316.52Source | -67.91Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 108,691Source | 514,369Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | -186,000Source | -116,000Source | — | — |
| General and Administrative ExpenseUSD | 5,033,000Source | 6,044,000Source | 4,587,000Source | 3,249,000Source |
| Interest ExpenseUSD | 317,000Source | 288,000Source | 11,000Source | 17,000Source |
| Investment Income, InterestUSD | 123,000Source | 14,000Source | — | — |
| Nonoperating Income (Expense)USD | 198,000Source | -956,000Source | -613,000Source | 691,000Source |
| Research and Development ExpenseUSD | 20,614,000Source | 28,049,000Source | 5,423,000Source | 2,505,000Source |